Clinical Trial Update: A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This is a Phase 1 study update for CC-97540, a CD19-targeted NEX-T CAR T cell therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma. The trial status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CC-97540

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Lymphoma Non-Hodgkin, Agressive Lymphoma | Phase 1 | Status: COMPLETED